Diagnosis of skeletal metastases in malignant extraskeletal cancers

Bone Cancer

Volumn , Issue , 2010, Pages 283-294

  Schirrmeister, Holger ^a   Arslandemir, Coskun ^b  

^a Westküstenklinikum Heide ^*  (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882827115     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374895-9.00024-4     Document Type: Chapter

References (45)

1. Rubens R.D., Fogelman I. Bone Metastases 1991, Springer-Verlag, London.
2. Orr F.W., Sanchez O.H., Kostenuik P., et al. Tumor interactions in skeletal metastasis. Clin Orthop 1995, 312:19-33.
3. Ledley R.S., Luisted L.B. Reasoning foundations of medical diagnosis, symbolic logic, probability, and value theory aid our understanding of how physicians reason. Science 1959, 130:9-21.
4. Munz D.L. Ist die Skelettszintigraphie zum Metastasenscreening noch erforderlich?. Nuklearmedizin 1994, 32:5-10.
5. Bachman A.S., Sproul E.E. Correlation of radiographic and autopsy findings in suspected metatases in the spine. Bull NY Acad Med 1940, 44:169-175.
6. Blau M. 18F-Fluoride for bone imaging. Semin Nucl Med 1972, 2:131-133.
7. 18F and skeletal radiography. Radiology 1973, 107:551-555.
8. Weber D.A., Keyes J.W., Landmann S., et al. Comparison of Tc-polyphosphate and F18 for bone imaging. Am J Roentgen Rad Ther Nucl Med 1974, 121:184-190.
9. Venz S., Hosten N., Friedrichs R., et al. Osteoplastische Knochenmetastasen beim Prostatakarzinom: Magnetresonanztomographie und Knochenmarkszintigraphie. Fortschr Röntgenstr 1994, 161:64-69.
10. Kosuda S., Tatsumi K., Yokoyama H., et al. Does bone SPECT actually have lower sensitivity for detecting vertebral metastases than MRI?. J Nucl Med 1996, 37:975-978.
11. Schirrmeister H., Guhlmann A.C., Elsner K., et al. Sensitivity in detecting osseous lesions depends on anatomical localization: planar bone scintigraphy vs 18F-PET. J Nucl Med 1999, 40:1623-1629.
12. Schirrmeister H., Glatting G., Hetzel J., et al. Prospective evaluation of the clinical value of planar bone scans, SPECT and 18F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med 2001, 42:1800-1804.
13. Hetzel M., Arslandemir C., Hetzel J., et al. F-18 NaF PET in lung cancer - Accuracy, cost-effectiveness and impact on patient management. J Bone Miner Res 2003, 18:2206-2214.
14. Jones A.E., Ghaed N., Dunson G.L., et al. Clinical evaluation of orally administered fluorine-18 for bone scanning. Radiology 1973, 107:129-131.
15. 99mTc-EHDP. Fortschr Röntgenstr 1975, 123:137-143.
16. 99mTc-EHDP. Fortschr Röntgenstr 1975, 123:313-318.
17. 99mTc-EHDP. Fortschr Röntgenstr 1975, 123:137-143.
18. 18F in rabbit bone. Clin Physiol Meas 1986, 7:333-343.
19. 18F fluoride kinetics in humans. J Nucl Med 1978, 19:1301-1309.
20. Krishnamurthy G.T., Huebotter R.J., Tubis M., et al. Pharmakokinetics of current skeletal-seeking radiopharmaceuticals. Am J Roentgen Rad Ther Nucl Med 1976, 126:293-301.
21. Goldhahn W.E., Goldhahn G., Mohsenipur I., et al. Degenerative Erkrankungen der Halswirbelsäule 1994, Hippokrates-Verlag, Stuttgard.
22. Schirrmeister H., Kotzerke J., Rentschler M., et al. Die Positronenemissionstomographie des Skelettsystems mit 18FNa: Häufigkeit, Befundmuster und Verteilung benigner Veränderungen. Fortschr Röntgenstr 1998, 169:309-314.
23. Dihlmann W. Röntgendiagnostische Basisinformation: Vertebralosteophyten. Akt Rheumatol 1977, 2:139-142.
24. W. Dihlmann, Gelenke, Wirbelverbindungen. 3. Aufl., Thieme, New York: Stuttgart (1987).
25. Erlemann R., Roessner A., Peters P.E., et al. Tumoröse Raumforderungen der Wirbelsäule. Fortschr. Röntgenstr 1987, 146:403-409.
26. Erlemann R., Reiser M., Roessner A., et al. Primäre Knochentumoren und tumorähnliche Läsionen in der Wirbelsäule. Fortschr Röntgenstr 1987, 147:131-137.
27. Frank J.A., Ling A., Patronas N.J., et al. Detection of malignant bone tumors: MR imaging vs scintigraphy. Amer J Roentgenol 1990, 155:1043-1048.
28. Reske S.N., Karstens J.H., Glöckner W.M., et al. Nachweis des Knochenmarksbefalls beim Mammakarzinom und bei malignen Lymphomen durch Immunszintigraphie des hämatopoetischen Knochenmarks. Fortschr Röntgenstr 1990, 152:60-66.
29. Traill Z., Richards M.A., Moore N.R. Magnetic resonance imaging of metastatic bone disease. Clin Orthop 1995, 312:76-88.
30. Pantel K., Izbicki J., Passlick B., et al. Frequency and prognostic significance of isolated tumor cells in bone marrow of patients with non-small-cell lung cancer without overt metastases. Lancet 1996, 347:649-653.
31. Schirrmeister H., Guhlmann A.C., Kotzerke J., et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with 18F-fluoride ion and positron emission tomography. J Clin Oncol 1999, 17:2381-2389.
32. Schirrmeister H., Kühn T., Guhlmann A.C., et al. [F-18] 2-deoxy-2-fluoro D-glucose PET in preoperative staging of breast cancer-comparison with the standard staging procedures. Eur J Nucl Med 2001, 28:351-358.
33. Yeh S.D., Imbriaco M., Larson S.M., et al. Detection of bony metastases of androgen-independent prostate cancer by FDG-PET. Nucl Med Biol 1996, 23:693-697.
34. Shreve P.D., Grossman H.B., Gross M.D., et al. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology 1996, 199:751-756.
35. Cook G.J., Houston S., Rubens R., et al. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 1998, 16:3375-3379.
36. Ohta M., Tokuda Y., Suzuki Y., et al. Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99mTc-MDP bone scintigraphy. Nucl Med Commun 2001, 22:875-879.
37. Yang S.N., Liang J.A., Lin F.J., et al. Comparing whole body (18)F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer. J Cancer Res Clin Oncol 2002, 128:325-328.
38. Kao C.H., Hsieh J.F., Tsai S.C., et al. Comparison and discrepancy of 18F-deoxyglucose-positron emission tomography and Tc-99m MDP bone scan to detect bone metastases. Anticancer Res 2000, 20:2189-2192.
39. Marom E.M., McAdams H.P., Erasmus J.J., et al. Staging non-small cell lung cancer with whole-body PET. Radiology 2002, 212:803-809.
40. Bury T., Barreto A., Daenen F., et al. Fluorine-18 deoxyglucose positron emission tomography for detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med 1998, 25:1244-1247.
41. Gayed I., Vu T., Johnson M., et al. Comparison of bone and [18]2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in the evaluation of bony metastases in lung cancer. Mol Imaging Biol 2003, 5:26-31.
42. Steinborn M.M., Heuck A.F., Tiling R., et al. Whole-body bone marrow MRI in patients with metastatic disease to the skeletal system. J Comput Assist Tomogr 1999, 23:123-129.
43. Layer G., Steudel A., Grünwald F., et al. Magnetic resonance imaging to detect bone marrow metastases in the initial staging of small cell lung carcinoma and breast carcinoma. Cancer 1999, 85:1004-1009.
44. Freedman G.M., Negendank W.G., Hudes G.R., et al. Preliminary results of a bone marrow magnetic resonance imaging protocol for patients with high risk prostate cancer. Urology 1999, 54:118-123.
45. Tausig A., Manthey N., Berger F., et al. Vorzüge und Limitationen der Ganzkörper-MRT mit Turbo-STIR Sequenzen im Vergleich zur planaren Skelettszintigraphie. Nuklearmedizin 2000, 39:174-179.